Lindsley Carol B
Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160-7330, USA.
Curr Rheumatol Rep. 2006 Jun;8(3):174-7. doi: 10.1007/s11926-996-0022-6.
Recent studies involving juvenile dermatomyositis indicate that the majority of affected children have symptoms suggestive of infection prior to disease onset, damage to skin and muscle each have a distinct pathophysiology, certain urinary muscle metabolites may be useful laboratory markers, and methotrexate used as first line therapy with corticosteroids is associated with greater height velocity and smaller increase in body mass index.
最近涉及青少年皮肌炎的研究表明,大多数受影响的儿童在疾病发作前有感染迹象,皮肤和肌肉损伤各有独特的病理生理学,某些尿肌代谢物可能是有用的实验室标志物,与皮质类固醇联合用作一线治疗的甲氨蝶呤与更高的身高增长速度和更小的体重指数增加相关。